| 前收市價 | 4,350.50 |
| 開市 | 4,324.85 |
| 買盤 | 4,360.55 x 0 |
| 賣出價 | 4,371.65 x 0 |
| 今日波幅 | 4,298.60 - 4,376.90 |
| 52 週波幅 | 2,497.60 - 5,514.65 |
| 成交量 | |
| 平均成交量 | 49,937 |
| 市值 | 724.987B |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 38.90 |
| 每股盈利 (最近 12 個月) | 無 |
| 業績公佈日 | 2020年10月28日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 2,581.68 |
- Insider Monkey
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2023 Earnings Call Transcript
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2023 Earnings Call Transcript January 25, 2023 Operator: Ladies and gentlemen, good day, and welcome to Dr. Reddy’s Laboratories Limited Q3 FY 2023 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions […]
- Benzinga
Intercept Settles Ocaliva Litigation With Reddy's Lab
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and its subsidiary Intercept Pharma Europe Limited settled patent litigation with Dr. Reddy’s Laboratories Ltd (NYSE: RDY). The litigation concerns the submission by Dr. Reddy’s of an Abbreviated New Drug Application seeking approval to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets before the expiration of the Company’s U.S. patents. Related: Intercept Shares Jump After Reissuing Annual Guidance. Under the terms of the
- Benzinga
Eton Pharma Shares Tick Higher After Offloading Hospital Products
Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its hospital products to Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories Ltd (NYSE: RDY), for $50 million. "The sale of our hospital products allows us to focus our resources on our core rare disease business, which is rapidly growing, and also provides an attractive opportunity to monetize the value we have created with our hospital products," said CEO Sean Brynjelsen, CEO of Eton. Dr. Reddy's purchased the Biorphen, Rezipre
